Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 33 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.1M | 0.00% | 94.10K | +43% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ANL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Ji PingDirector | Sale at price 15.77 - 16.03 per share. | 10.2K | $163.28K |
| Sep 21, 2026 | Ji PingDirector | Sale at price 16.63 per share. | 5K | $83.15K |
| Aug 25, 2026 | Ye XiaofengChief Financial Officer | Sale at price 13.98 - 14.25 per share. | 11.7K | $164.63K |
| May 12, 2026 | Lu YangChief Executive Officer | Sale at price 13.18 per share. | 10 | $132 |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 648.6 | -26.1 | -12.0 | 106.2 | -16.3 | -3.7 | 13.0 | 9.2 | 12.8 | -32.0 | +666.2% | ||
| 2025 | -21.0 | 6.6 | -11.1 | -8.5 | -1.1 | -19.2 | -2.7 | 18.2 | 6.4 | -20.5 | 11.2 | -10.7 | −47.1% |
| 2024 | 1.6 | -21.7 | 24.2 | 55.4 | -47.4 | -55.1 | 7.4 | -19.1 | -29.9 | 0.8 | 11.5 | 20.4 | −70.1% |
| 2023 | -46.3 | 36.6 | -18.3 | −40.1% |
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.
Buy / hold / sell counts